ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Ailing Zhong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4646-0438; OpenAlex author ID A5063076627. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper

Papers 4

Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic fac… First author DOI 10.1080/02656736.2023.2278417 ↗
Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. Co-author DOI 10.1097/md.0000000000023863 ↗
Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.520330 ↗
Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2019/1356264 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chien‐shan Cheng · 3 shared papers, 2019–2023 · strength 0.47
Zhiqiang Meng · 2 shared papers, 2019–2023 · strength 0.32
- Paper Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a r… DOI 10.1080/02656736.2023.2278417 ↗
- Paper Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. DOI 10.1155/2019/1356264 ↗
Lin Guo · 2 shared papers, 2020 · strength 0.28
- Paper Clinical Significance of Glucose to Lymphocyte Ratio (GLR) as a Prognostic Marker for Patients With Pancreatic Cancer. DOI 10.3389/fonc.2020.520330 ↗
- Paper Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. DOI 10.1097/md.0000000000023863 ↗
Huili Zhu · 1 shared paper, 2023 · strength 0.22
- Paper Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a r… DOI 10.1080/02656736.2023.2278417 ↗
Shu Dong · 1 shared paper, 2023 · strength 0.22
- Paper Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a r… DOI 10.1080/02656736.2023.2278417 ↗
Kun Wang · 1 shared paper, 2023 · strength 0.22
- Paper Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a r… DOI 10.1080/02656736.2023.2278417 ↗
Yiwen Yu · 1 shared paper, 2020 · strength 0.13
- Paper Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. DOI 10.1097/md.0000000000023863 ↗
Zhen Chen · 1 shared paper, 2019 · strength 0.10
- Paper Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. DOI 10.1155/2019/1356264 ↗
Lianyu Chen · 1 shared paper, 2019 · strength 0.10
- Paper Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. DOI 10.1155/2019/1356264 ↗
Wei Chiang Liu · 1 shared paper, 2019 · strength 0.10
- Paper Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. DOI 10.1155/2019/1356264 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.